BRPI0607833A2 - uso de defibrotídeo e/ou oligodesoxirribonucleotídeos - Google Patents

uso de defibrotídeo e/ou oligodesoxirribonucleotídeos

Info

Publication number
BRPI0607833A2
BRPI0607833A2 BRPI0607833A BRPI0607833A BRPI0607833A2 BR PI0607833 A2 BRPI0607833 A2 BR PI0607833A2 BR PI0607833 A BRPI0607833 A BR PI0607833A BR PI0607833 A BRPI0607833 A BR PI0607833A BR PI0607833 A2 BRPI0607833 A2 BR PI0607833A2
Authority
BR
Brazil
Prior art keywords
defibrotide
oligodeoxyribonucleotides
tumors
produced
oligotide
Prior art date
Application number
BRPI0607833A
Other languages
English (en)
Inventor
Eissner Günter
Iris Ferro Laura
Lacobelli Massimo
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Priority claimed from PCT/EP2006/060304 external-priority patent/WO2006094916A1/en
Publication of BRPI0607833A2 publication Critical patent/BRPI0607833A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0607833A 2005-03-03 2006-02-27 uso de defibrotídeo e/ou oligodesoxirribonucleotídeos BRPI0607833A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000336A ITMI20050336A1 (it) 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale
US73140405P 2005-10-28 2005-10-28
PCT/EP2006/060304 WO2006094916A1 (en) 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors

Publications (1)

Publication Number Publication Date
BRPI0607833A2 true BRPI0607833A2 (pt) 2017-05-30

Family

ID=39085989

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0607833A BRPI0607833A2 (pt) 2005-03-03 2006-02-27 uso de defibrotídeo e/ou oligodesoxirribonucleotídeos
BRPI0608259A BRPI0608259A2 (pt) 2005-03-03 2006-02-27 uso de oligodesoxírribonucleotídeos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0608259A BRPI0608259A2 (pt) 2005-03-03 2006-02-27 uso de oligodesoxírribonucleotídeos

Country Status (9)

Country Link
EP (1) EP1867335B1 (pt)
CN (3) CN101123973A (pt)
AT (1) ATE514427T1 (pt)
BR (2) BRPI0607833A2 (pt)
DK (1) DK1867335T3 (pt)
ES (1) ES2366486T3 (pt)
IT (1) ITMI20050336A1 (pt)
PT (1) PT1867335E (pt)
ZA (1) ZA200707417B (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
WO1998054313A2 (en) * 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN

Also Published As

Publication number Publication date
CN101254204A (zh) 2008-09-03
PT1867335E (pt) 2011-09-06
CN101232892A (zh) 2008-07-30
EP1867335A2 (en) 2007-12-19
EP1867335B1 (en) 2011-06-29
ATE514427T1 (de) 2011-07-15
ITMI20050336A1 (it) 2006-09-04
BRPI0608259A2 (pt) 2016-10-11
DK1867335T3 (da) 2011-08-01
ZA200707417B (en) 2008-12-31
CN101123973A (zh) 2008-02-13
ES2366486T3 (es) 2011-10-20
EP1867335A3 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
DOP2011000199A (es) Compuestos heterociclocos y metodos de uso
ATE519508T1 (de) Medizinische ballons
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
CY1114441T1 (el) Συνδετικες ενωσεις, ανοσογονικες ενωσεις και πεπτιδομιμητικα
MX346924B (es) Compuestos de diarilhidantoina.
ATE518559T1 (de) Mikrobearbeitete medizinprodukte
DE602006017829D1 (de) Oberflächenbehandlungszusammensetzungen mit saccharid-siloxan-polymeren
PT2518509E (pt) Diagnóstico molecular e classificação de melanoma maligno com base em marcadores seleccionados da listagem que consiste em rgs1, ncoa3, spp1, phip
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
PT1560812E (pt) Compostos de aminociclohexil eter e suas utilizacoes
WO2006094917A8 (en) Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors
WO2010033773A3 (en) Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways
CL2007002951A1 (es) Uso de compuestos derivados de espiroheterociclicos en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer.
WO2007100920A3 (en) Diagnosis and treatment of prostate cancer
WO2009105457A3 (en) Slit2 cancer markers
ATE527998T1 (de) Illudin-analoga als krebsmittel
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2007056049A3 (en) Molecular profiling of cancer
WO2007134132A3 (en) Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
EP2298074A3 (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
MX2009007543A (es) Conjugados de polimero de posaconazol y metodos de tratamiento usando los conjugados de posaconazol y polimero.
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law
B11O Dismissal: republication [chapter 11.15 patent gazette]

Free format text: O DESPACHO PUBLICADO NA RPI 2092 DE 08/02/2011 REFERE-SE A PETICAO 20070122605/RJ DE 31/08/2007.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]